Gimv: strengthens position in immuno-oncology
(CercleFinance.com) - Gimv has increased its stake in ImCheck Therapeutics, an emerging player in the field of cancer and auto-immune immunotherapies, whereby the Belgian portfolio company seeks to strengthen its position.
The company said that it has participated in ImCheck's latest financing round of 53 million dollars, that was co-led by US health giant Pfizer and French state-owned bank Bpifrance.
The proceeds will be used to fund the initial clinical trial of ImCheck's monoclonal antibody ICT01, to further expand its pipeline of immunomodulators and to bring additional immuno-oncology programs into the clinic, Gimv said.
Copyright (c) 2019 CercleFinance.com. All rights reserved.